2026-06-14T02:29:32Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/167312024-11-28T18:51:55Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16963col_20.500.12105_16964

00925njm 22002777a 4500 dc Romera Martínez, Irene author Avendaño-Solá, Cristina author Villegas Da Ros, Carolina author Bosch Llobet, Alba author García Erce, José Antonio author González Fraile, María Isabel author Guerra Domínguez, Luisa author Vicuña Andrés, Isabel author Anguita Velasco, Javier author González Rodríguez, Victoria Paz author Contreras, Enric author Urcelay Uranga, Sabin author Pajares Herraiz, Ángel Luis author Jimenez-Marco, Teresa author Ojea Pérez, Ana María author Arroyo Rodríguez, José Luis author Perez-Olmeda, Mayte author Ramos-Martínez, Antonio author Velasco-Iglesias, Ana author Bueno Cabrera, José Luis author Duarte, Rafael F author 2024 Background and objectives: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study ConPlas-19 donors and characteristics that associate with high anti-SARS-CoV-2 antibody levels. Materials and methods: Four-hundred donors were enrolled in ConPlas-19. The presence and titres of anti-SARS-CoV-2 antibodies were evaluated by EUROIMMUN anti-SARS-CoV-2 S1 IgG ELISA. Results: A majority of 80.3% of ConPlas-19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti-SARS-CoV-2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24-3.42), with more than 7 days of COVID-19 symptoms (RR 1.89; 95% CI 1.05-3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16-5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91-3.06). Conclusion: SARS-CoV-2 CP candidate donors' age, duration of COVID-19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID-19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks. Vox Sang. 2024 Jan;119(1):27-33. 10.1111/vox.13561 1423-0410 Vox sanguinis 37986640 http://hdl.handle.net/20.500.12105/16731 anti-SARS-CoV-2 Convalescent plasma COVID-19 Donors Passive immunotherapy Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial